Alegori study: efficacy of a bevacizumab nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT). A randomized trial against placebo with dose selection

Affiliation auteurs!!!! Error affiliation !!!!
TitreAlegori study: efficacy of a bevacizumab nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT). A randomized trial against placebo with dose selection
Type de publicationJournal Article
Year of Publication2015
AuteursDupuis-Girod S., Fargeton A-E, Paez C., Ambrun A., Decullier E., Roux A., Breant V, Beni K., Riviere S., Lacombe P., Dufour X., Harle J.R, Babin E., Carette M.F, Corre R., Duffau P., Hatron P.Y, Kaminsky P., Lavigne C., Lorcerie B., Porcher R., Faure F.
JournalANGIOGENESIS
Volume18
Pagination538-539
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN0969-6970